Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled the launch of WHAT THE C@H?!, an educational initiative designed to address the information gap surrounding congenital adrenal hyperplasia (CAH) and acknowledge the challenges faced by the community in managing this condition. “We…
CVS Health® (NYSE: CVS) revealed today a significant investment of $19.2 million, facilitated via Boston Financial, earmarked for the construction of 85 new affordable housing units in Arvada, Colorado. This initiative, executed in partnership with Family Tree and BlueLine Development,…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled positive top-line results from its Phase 2 SAVITRI™ trial. This study, employing a randomized, double-blind, and placebo-controlled design, evaluated the efficacy and safety of NBI-1065845 in adult patients grappling with major depressive disorder…
Pfizer Inc. (NYSE: PFE) has received approval from the European Commission (EC) for EMBLAVEO® (aztreonam-avibactam), expanding treatment options for adult patients facing complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including…
GSK plc (LSE/NYSE: GSK) has unveiled encouraging outcomes from the pivotal EAGLE-1 phase III trial concerning gepotidacin, a prospective first-in-class oral antibiotic offering a novel approach to combat uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. These findings are slated…
AbbVie (NYSE: ABBV) has announced encouraging findings from its Phase 3 trial, SELECT-GCA, showcasing positive top-line results. The trial, conducted across multiple centers, employed a randomized, double-blind, placebo-controlled design. It investigated the efficacy of upadacitinib (marketed as RINVOQ®) in combination…
Cerevel Therapeutics (Nasdaq: CERE) has released encouraging findings from its pivotal Phase 3 TEMPO-3 trial for tavapadon, a unique D1/D5 receptor partial agonist investigated as a once-daily treatment for Parkinson’s disease. This trial assessed tavapadon’s efficacy, safety, and tolerability as…
A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO) on 12 April. The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines but a simplified formulation, allowing opportunities to rapidly increase production…
Today, the joint effort of the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) culminated in the publication of a comprehensive report detailing the outcomes of their recent workshop on COVID-19 vaccine strain updates. Conducted…
Sanofi’s frexalimab, a CD40L antibody, has displayed enduring effectiveness and favorable tolerability over almost a year in individuals with relapsing multiple sclerosis (MS). These findings will be unveiled today at the American Academy of Neurology (AAN) 2024 Annual Meeting in…
Alert Overview This alert from the World Health Organization (WHO) addresses the discovery of falsified DOW USP/EP Propylene Glycol in Pakistan. Authentic DOW USP/EP Propylene Glycol is a crucial raw material used in pharmaceutical and other manufacturing processes, meeting the…
Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In this interim analysis, patients treated with Fabhalta experienced a significant…
